Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00:02 2023-01-26 pm EST
168.89 USD   -0.37%
04:50pSector Update: Healthcare Stocks Climb Back to Finish Higher
MT
09:12aSector Update: Health Care Stocks Advance Pre-Bell Thursday
MT
05:39aEvotec, Johnson & Johnson's Janssen Biotech Enter Cancer Drug Development Collaboration
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson's Janssen Global Services Unit Says No Plans to Bid for Horizon Therapeutics

12/05/2022 | 07:15am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. -0.65% 254.88 Delayed Quote.-2.95%
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY -1.55% 111.25 Delayed Quote.-0.70%
JOHNSON & JOHNSON -0.37% 168.89 Delayed Quote.-4.04%
SANOFI -0.21% 89.72 Real-time Quote.-0.13%
All news about JOHNSON & JOHNSON
04:50pSector Update: Healthcare Stocks Climb Back to Finish Higher
MT
09:12aSector Update: Health Care Stocks Advance Pre-Bell Thursday
MT
05:39aEvotec, Johnson & Johnson's Janssen Biotech Enter Cancer Drug Development Collaboration
MT
05:25aEvotec Shares Climb After Agreement With Janssen on Immunotherapies Development
DJ
04:07aEvotec Starts Oncology-development Collaboration With Johnson & Johnson Unit
MT
01/25Johnson & Johnson : JNJ-USQ_Transcript_FINAL 2023-01-24
PU
01/25Morgan Stanley Adjusts Price Target on Johnson & Johnson to $180 From $176, Maintains E..
MT
01/25Atlantic Equities Adjusts Johnson & Johnson's Price Target to $168 From $160, Keeps Neu..
MT
01/25MarketScreener's World Press Review, January 25
MS
01/25RLS Global Chairman to Depart in February; Successor Nominated
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 017 M - -
Net income 2022 20 668 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 21,3x
Yield 2022 2,61%
Capitalization 442 B 442 B -
EV / Sales 2022 4,53x
EV / Sales 2023 4,30x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 168,89 $
Average target price 181,45 $
Spread / Average Target 7,44%
EPS Revisions
Managers and Directors
Joaquin Duato Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
James D. Swanson Global Chief Information Officer & Executive VP
Dan Zelem Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-4.04%443 181
ELI LILLY AND COMPANY-4.40%332 306
NOVO NORDISK A/S1.07%313 303
ROCHE HOLDING AG1.07%281 267
MERCK & CO., INC.-3.68%275 319
ABBVIE INC.-8.79%261 275